ZIOPHARM Oncology Inc
Most Recent
Will Genocea Stock Bounce Back? In-Depth Analysis
Today, we’re taking a close look at Genocea (GNCA) to show why the stock could bounce back after fluctuating significantly over the last year.
Cell Therapy Market Could Boost Celgene’s Long-Term Growth
With the acquisition of Juno Therapeutics, Celgene will benefit from all of Juno Therapeutics’ facilities related to cell therapy.
Behind Celgene’s Strategy in the Juno Therapeutics Acquisition
With the acquisition of Juno Therapeutics (JUNO), Celgene (CELG) will likely become an established cellular immunotherapy company.
How Did Ziopharm Keep XBI from Losing More Ground?
Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV ratio of 10.1x.